Carsten P Ade
Overview
Explore the profile of Carsten P Ade including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
573
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mamontova V, Trifault B, Gribling-Burrer A, Bohn P, Boten L, Preckwinkel P, et al.
Genes Dev
. 2024 Oct;
38(17-20):915-930.
PMID: 39362776
Long noncoding (lnc)RNAs emerge as regulators of genome stability. The nuclear-enriched abundant transcript 1 (NEAT1) is overexpressed in many tumors and is responsive to genotoxic stress. However, the mechanism that...
2.
Vidal R, Leen E, Herold S, Muller M, Fleischhauer D, Schulein-Volk C, et al.
Elife
. 2024 Aug;
13.
PMID: 39177021
MYC family oncoproteins regulate the expression of a large number of genes and broadly stimulate elongation by RNA polymerase II (RNAPII). While the factors that control the chromatin association of...
3.
Gaballa A, Gebhardt-Wolf A, Krenz B, Mattavelli G, John M, Cossa G, et al.
Nat Commun
. 2024 Feb;
15(1):1446.
PMID: 38365788
In pancreatic ductal adenocarcinoma (PDAC), endogenous MYC is required for S-phase progression and escape from immune surveillance. Here we show that MYC in PDAC cells is needed for the recruitment...
4.
Trifault B, Mamontova V, Cossa G, Ganskih S, Wei Y, Hofstetter J, et al.
Nucleic Acids Res
. 2024 Jan;
52(6):3050-3068.
PMID: 38224452
RNA-binding proteins emerge as effectors of the DNA damage response (DDR). The multifunctional non-POU domain-containing octamer-binding protein NONO/p54nrb marks nuclear paraspeckles in unperturbed cells, but also undergoes re-localization to the...
5.
Jessen M, Gertzmann D, Liss F, Zenk F, Bahner L, Schoffler V, et al.
Oncogene
. 2024 Jan;
43(8):578-593.
PMID: 38182898
YAP activation in cancer is linked to poor outcomes, making it an attractive therapeutic target. Previous research focused on blocking the interaction of YAP with TEAD transcription factors. Here, we...
6.
Fetiva M, Liss F, Gertzmann D, Thomas J, Gantert B, Vogl M, et al.
Nucleic Acids Res
. 2023 Mar;
51(9):4266-4283.
PMID: 36864753
YAP, the key protein effector of the Hippo pathway, is a transcriptional co-activator that controls the expression of cell cycle genes, promotes cell growth and proliferation and regulates organ size....
7.
Hanselmann S, Gertzmann D, Shin W, Ade C, Gaubatz S
Cell Cycle
. 2022 Sep;
22(4):419-432.
PMID: 36135961
Protein regulator of cytokinesis 1 (PRC1) is a microtubule-binding protein with essential roles in mitosis and cytokinesis. PRC1 is frequently overexpressed in cancer cells where it could contribute to chromosomal...
8.
Otto C, Kastner C, Schmidt S, Uttinger K, Baluapuri A, Denk S, et al.
Mol Oncol
. 2022 Jun;
16(15):2788-2809.
PMID: 35673898
Ribosomal biogenesis and protein synthesis are deregulated in most cancers, suggesting that interfering with translation machinery may hold significant therapeutic potential. Here, we show that loss of the tumor suppressor...
9.
Krenz B, Gebhardt-Wolf A, Ade C, Gaballa A, Roehrig F, Vendelova E, et al.
Cancer Res
. 2021 Jun;
81(16):4242-4256.
PMID: 34145038
Deregulated expression of the MYC oncoprotein enables tumor cells to evade immune surveillance, but the mechanisms underlying this surveillance are poorly understood. We show here that endogenous MYC protects pancreatic...
10.
Roeschert I, Poon E, Henssen A, Dorado Garcia H, Gatti M, Giansanti C, et al.
Nat Cancer
. 2021 Mar;
2(3):312-326.
PMID: 33768209
Amplification of is the driving oncogene in a subset of high-risk neuroblastoma. The MYCN protein and the Aurora-A kinase form a complex during S phase that stabilizes MYCN. Here we...